Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

Trial Identifier:	D133HR00022
Sponsor:	AstraZeneca
Collaborator:	Hospital Israelita Albert Einstein
Start Date:	July 2023
Primary Completion Date:	June 2024
Study Completion Date:	June 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Brazil	Belo Horizonte, Brazil
Brazil	Recife, Brazil
Brazil	Salvador, Brazil
Brazil	Sao Paulo, Brazil

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.